a 2022

Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia

TAEHYUNG, K., Daniela ŽÁČKOVÁ, Ivana JEŽÍŠKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK et. al.

Basic information

Original name

Somatic mutations in myeloid transcription factors and in activated signaling pathway, but not in epigenetic modifier pathway, predict the risk of tratment failure and progression to advanced phase in chronic myeloid leukemia

Authors

TAEHYUNG, K., Daniela ŽÁČKOVÁ, Ivana JEŽÍŠKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, YS. YOO, H. LEE, KH. KIM, MH. CHANG, SY. YI, J. MEDEIROS, S. ABELSON and D. KIM

Edition

64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood, 2022

Other information

Type of outcome

Konferenční abstrakt

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine
Změněno: 20/12/2022 14:57, Bc. Kateřina Kolesová
Displayed: 1/11/2024 04:29